Boston, MA -- (SBWIRE) -- 08/18/2016 -- COPD is a chronic disease condition with a combination of symptoms of both chronic bronchitis and emphysema. Chronic bronchitis results in inflammation in the bronchioles, which results in increased mucus production. The condition is usually associated with a long-term cough with mucus. Emphysema results in the destruction of the walls of the alveoli, resulting in difficulty in breathing.

Technavio's analysts forecast the global chronic obstructive pulmonary disease (COPD) drugs market to grow at a CAGR of 4.85% during the period 2016-2020.

Get More Details on this Report and a Full Table of Contents at Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020

Covered in this report
The report covers the present scenario and the growth prospects of the global chronic obstructive pulmonary disease (COPD) drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat COPD.

The market is divided into the following segments based on geography:

-Americas
-APAC
-EMEA

Technavio's report, Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-AstraZeneca
-Boehringer Ingelheim
-GSK
-Merck
-Novartis
-Teva

Other prominent vendors

-Ache Laboratorios Farmaceuticos
-Almirall
-Aquinox Pharmaceuticals
-Ario Pharma
-Asmacure
-Astellas Pharma
-BioMarck Pharmaceuticals
-Chiesi Farmaceutici
-Cytokinetics
-F. Hoffmann-La Roche
-Gilead Sciences
-Innoviva
-Invion
-MediciNova
-Mereo BioPharma
-Mylan
-Orion Corporation
-Palobiofarma
-Pearl Therapeutics
-Pharmaxis
-Prosonix
-Pulmagen Therapeutics
-RespiVert
-SolAeroMed
-Sunovion Pharmaceuticals
-Theravance Biopharma
-Theron Pharmaceuticals
-Verona Pharma
-Xention
-Yungjin Pharm
-ZAI Lab

Market driver

-Uptake of LABA/LAMA combination therapies
-For a full, detailed list, view our report

Market challenge

-Negligence toward use of controller medications
-For a full, detailed list, view our report

Market trend

-Increased adoption of e-cigarettes and smoking cessation products
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2020 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, Asmacure, Astellas Pharma, BioMarck Pharmaceuticals, Chiesi Farmaceutici, Cytokinetics, F. Hoffmann-La Roche, Gilead Sciences, Innoviva, Invion, MediciNova, Mereo BioPharma, Mylan, Orion Corporation, Palobiofarma, Pearl Therapeutics, Pharmaxis, Prosonix, Pulmagen Therapeutics, RespiVert, SolAeroMed, Sunovion Pharmaceuticals, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention, Yungjin Pharm, ZAI Lab.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

-Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H1, 2016
-Obstructive Pulmonary Disease Global Clinical Trials Review, H2, 2015
-Obstructive Pulmonary Disease Global Clinical Trials Review, H1, 2016
-Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation
-COPD Drugs Market in China 2016-2020